Investor conferences put Axcelis Technologies back in focus
Axcelis Technologies (ACLS) has drawn fresh attention after confirming participation in upcoming investor conferences, including the Citi 2026 Global TMT Conference and the B. Riley Securities Consumer & TMT Conference.
Recent moves in Axcelis Technologies reflect that tension between interest in the story and changing risk perception, with the share price down about 21% over the past month and roughly 25% over 90 days, yet still showing a 28.16% year to date share price return and a 5 year total shareholder return of 125.89%.
Spot opportunities around Axcelis Technologies by scanning a curated 55 AI infrastructure stocks.Axcelis Technologies has a solid business selling ion implantation tools into a critical part of the chip making process, yet the stock has just pulled back hard after a strong run. Is that quality now on sale, or is it still priced rich?
Most Popular Narrative: 34.9% Undervalued
At a last close of $110.37, the most followed Axcelis Technologies narrative points to a fair value of about $169.67, which implies a wide valuation gap that investors are now reassessing as guidance and conference commentary arrive.
As the installed base of Axcelis tools grows, recurring revenue from higher-margin services, parts, and upgrades (CS&I) continues to increase, providing resilience and predictability to cash flows and supporting improved earnings even during cyclical downturns.
Read the complete narrative. Read the complete narrative.
Want to understand why this Axcelis Technologies view supports such a different price than the market? The story leans on modest top line growth, shifting margins, and a richer future earnings multiple that needs to hold up over time. The tension between those inputs and today’s share price is what makes the full narrative worth a closer look.
Result: Fair Value of $169.67 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Axcelis Technologies still faces concentration in China and a reliance on mature node demand, which could quickly challenge the underpriced quality narrative if conditions shift.
Find out about the key risks to this Axcelis Technologies narrative.
Another angle on Axcelis Technologies valuation
While the popular Axcelis Technologies narrative points to a fair value of $169.67 and flags the stock as undervalued, Simply Wall St's DCF model paints a much harsher picture. On that view, Axcelis screens as expensive at $110.37 compared with an estimated future cash flow value of $10.85. Which story do you think better reflects the risks around earnings quality and cyclicality?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Axcelis Technologies for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 52 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
With Axcelis Technologies pulling in both concern and optimism, now is a good time to look through the numbers yourself and decide what matters most. Use the breakdown of 2 key rewards and 2 important warning signs
Looking for more investment ideas beyond Axcelis Technologies?
If you want to stress test your Axcelis Technologies view and uncover fresh ideas, spend a few focused minutes with these targeted stock lists before the next move passes you by.
- Pinpoint potential bargains by scanning companies that combine quality fundamentals with attractive pricing through the 52 high quality undervalued stocks.
- Strengthen your income side by reviewing resilient payers featured as 11 dividend fortresses.
- Protect your downside by checking companies with steadier profiles using the 79 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com